Establishing a Platform for Personalized Approach to the Management of Pancreatic Adenocarcinoma Using Patient-Derived Tumoroids

Mayo Clinic0 sitesJanuary 1, 2022

ConditionsPancreas Adenocarcinoma

Overview

Phase: N/A
Intervention: Not specified
Conditions: Pancreas Adenocarcinoma
Sponsor: Mayo Clinic
Primary Endpoint: Rate of the successful establishment of pancreatic patient-derived tumoroids (PDT)
Status: Withdrawn
Last Updated: 4 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

This study is designed to prospectively investigate the feasibility of establishing patient-derived tumoroids (PDT) as a platform for a personalized approach for response prediction and guide optimal neoadjuvant and/or adjuvant approach. PDT will be investigated to determine drug sensitivity, predict the response to chemotherapy agents and radiation therapy, and validate this response in treated patients, and to establish the feasibility of PDT as a platform for a personalized approach to guide multimodality treatment.

Registry

clinicaltrials.gov

Start Date

January 1, 2022

End Date

December 31, 2023

Last Updated

4 years ago

Study Type

Interventional

Study Design

Single Group

Sex

All

Investigators

Sponsor

Mayo Clinic

Responsible Party

Principal Investigator

Panagiotis Z. Anastasiadis

Principal Investigator

Mayo Clinic

Eligibility Criteria

Inclusion Criteria

•Age ≥ 18 years of age.
•Have an ECOG Performance Status of ≤
•No evidence of distant metastasis on imaging.
•Histologic or cytologic proven adenocarcinoma of the pancreas.
•Providing informed consent prior to enrollment in the trial.

Exclusion Criteria

•Failure to obtain additional core needle biopsies for generating PDTs.
•Females who are pregnant or plan to become pregnant.

Outcomes

Primary Outcomes

Rate of the successful establishment of pancreatic patient-derived tumoroids (PDT)

Time Frame: 2 years

Secondary Outcomes

PDT validation with a comparative analysis of patients' response to neoadjuvant chemotherapy and radiation(2 years)
Drug sensitivity and response prediction of radiation therapy in PDT(2 years)
Drug sensitivity and response prediction of chemotherapy agents in PDT(2 years)